Patient characteristics* stratified by those who did and did not use DANBIO-from-home at least once during the study period (1.5 years after launching of system)
| Data entry, DANBIO-from-home N=33 776 | Available data (%) | |||
| Yes 22 990 (68%) | No 10 786 (32%) | 100% | ||
| Gender, female | 14 614 (64%) | 3914 (36%) | 100 | |
| Age, strata (years) | <40 | 2231 (10%) | 1386 (13%) | 100 |
| 40–60 | 8288 (36%) | 3104 (29%) | ||
| 61–80 | 11 327 (49%) | 4479 (42%) | ||
| >80 | 1144 (5%) | 1817 (17%) | ||
| Age (years), median (IQR) | 62 (52–71) | 65 (50–77) | ||
| Diagnosis | Rheumatoid arthritis | 14 661 (64%) | 7081 (66%) | 100 |
| Axial spondyloarthritis | 3991 (17%) | 1832 (17%) | ||
| Psoriatic arthritis | 4338 (19%) | 1873 (17%) | ||
| Biological treatment, yes | 8462 (37%) | 3133 (29%) | 100 | |
| PASS†, yes | 14 270 (62%) | 5902 (55%) | 84 | |
| PASS†, no | 5559 (24%) | 2589 (24%) | ||
| Time since diagnosis (years), median (IQR) | 9 (5-16) | 10 (5–17) | 93 | |
| HAQ, median (IQR) | 0.5 (0.125–1.0) | 0.625 (0.125–1.25) | 87 | |
| Patient global, VAS, 0–100 mm | 31 (12–60) | 36 (14–64) | 90 | |
| Pain, VAS, 0–100 mm | 28 (11–52) | 31 (12–56) | 89 | |
| Fatigue, VAS, 0–100 mm | 42 (18–69) | 48 (20–73) | 89 | |
| Anchor‡, better/unchanged | 13 698 (60%) | 5750 (53%) | 85 | |
| Anchor‡, worse | 6285 (27%) | 2863 (27%) | ||
Values are patient numbers and column percentages (does not add to 100% in case of missingness), unless otherwise indicated.
*By March 2020 or latest visit before this date (baseline).
†PASS: ‘Consider how your arthritis has affected you in the last 48 hours. If you in the coming months felt similarly, would that be acceptable for you? Yes or no’.
‡Anchor: ‘Since your last visit, has your arthritis become: much better, a little better, better, unchanged, worse, a little worse, much worse’. In the table dichotomised into better/unchanged versus worse.
HAQ, Health Assessment Questionnaire; PASS, Patient Acceptable Symptom Scale; VAS, Visual Analogue Scale.